BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 339 filers reported holding BIO-TECHNE CORP in Q2 2018. The put-call ratio across all filers is 3.84 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,018,913 | -17.8% | 132,495 | -1.4% | 0.01% | -12.5% |
| Q2 2023 | $10,973,896 | +9.5% | 134,435 | -0.4% | 0.02% | 0.0% |
| Q1 2023 | $10,018,008 | -11.0% | 135,032 | -0.6% | 0.02% | -15.8% |
| Q4 2022 | $11,255,219 | +19.1% | 135,801 | +309.5% | 0.02% | +18.8% |
| Q3 2022 | $9,452,000 | -26.9% | 33,165 | -10.7% | 0.02% | -23.8% |
| Q2 2022 | $12,923,000 | -14.2% | 37,149 | +6.8% | 0.02% | +5.0% |
| Q1 2022 | $15,056,000 | -14.2% | 34,768 | -0.4% | 0.02% | -9.1% |
| Q4 2021 | $17,555,000 | +0.2% | 34,901 | +2.6% | 0.02% | -8.3% |
| Q3 2021 | $17,528,000 | +34.0% | 34,004 | +17.0% | 0.02% | +33.3% |
| Q2 2021 | $13,084,000 | -61.9% | 29,059 | -67.7% | 0.02% | -65.4% |
| Q1 2021 | $34,380,000 | +6.8% | 90,016 | -11.2% | 0.05% | -3.7% |
| Q4 2020 | $32,188,000 | +47.8% | 101,361 | +15.3% | 0.05% | +31.7% |
| Q3 2020 | $21,775,000 | -43.9% | 87,899 | -40.3% | 0.04% | -44.6% |
| Q2 2020 | $38,848,000 | +223.8% | 147,112 | +132.5% | 0.07% | +184.6% |
| Q1 2020 | $11,996,000 | +53.3% | 63,262 | +77.5% | 0.03% | +116.7% |
| Q4 2019 | $7,823,000 | +62.6% | 35,637 | +45.0% | 0.01% | +50.0% |
| Q3 2019 | $4,811,000 | -6.7% | 24,579 | -0.6% | 0.01% | 0.0% |
| Q2 2019 | $5,156,000 | +16.0% | 24,729 | +10.5% | 0.01% | +14.3% |
| Q1 2019 | $4,445,000 | +35.8% | 22,389 | -1.0% | 0.01% | +16.7% |
| Q4 2018 | $3,272,000 | -34.3% | 22,609 | -7.3% | 0.01% | -14.3% |
| Q3 2018 | $4,977,000 | -63.2% | 24,384 | -73.3% | 0.01% | -65.0% |
| Q2 2018 | $13,510,000 | +19.3% | 91,314 | +21.8% | 0.02% | +17.6% |
| Q1 2018 | $11,321,000 | +264.4% | 74,954 | +212.5% | 0.02% | +325.0% |
| Q4 2017 | $3,107,000 | +8.1% | 23,985 | +0.9% | 0.00% | 0.0% |
| Q3 2017 | $2,874,000 | +3.8% | 23,775 | +0.9% | 0.00% | 0.0% |
| Q2 2017 | $2,768,000 | +17.2% | 23,555 | +1.4% | 0.00% | 0.0% |
| Q1 2017 | $2,361,000 | +4.6% | 23,225 | +5.8% | 0.00% | 0.0% |
| Q4 2016 | $2,257,000 | -7.7% | 21,947 | -1.7% | 0.00% | 0.0% |
| Q3 2016 | $2,444,000 | -4.5% | 22,323 | -1.6% | 0.00% | 0.0% |
| Q2 2016 | $2,558,000 | +21.0% | 22,683 | +1.4% | 0.00% | 0.0% |
| Q1 2016 | $2,114,000 | +2.3% | 22,363 | -2.6% | 0.00% | 0.0% |
| Q4 2015 | $2,067,000 | -0.9% | 22,963 | +1.8% | 0.00% | 0.0% |
| Q3 2015 | $2,086,000 | -11.8% | 22,563 | -6.0% | 0.00% | 0.0% |
| Q2 2015 | $2,364,000 | -11.2% | 24,003 | -9.5% | 0.00% | -20.0% |
| Q1 2015 | $2,661,000 | -65.9% | 26,533 | -68.5% | 0.01% | -64.3% |
| Q4 2014 | $7,795,000 | – | 84,363 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
| Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
| Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
| Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
| STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
| Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
| Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
| DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
| Westwind Capital | 27,931 | $7,932,000 | 2.78% |
| MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |